Most downloaded articles:
'Editor's Picks'
Biotechnology Advances around the World & Industry News
Silent hypoxia and poor oxygenation in patients with early COVID-19
Hypoxia is a serious medical condition when oxygen levels in the body are abnormally low. Because of hypoxia's ability to quietly inflict severe damage, it is called silent hypoxia. Recently, research focus has been to study how the novel coronavirus attacks the lungs and other parts of the body. Biomedical engineers in the USA has studied lung perfusion abnormalities based on computer modeling to explain early COVID-19 hypoxemia. They reported their findings in Nature Communications (Nature Communications, 2020; 11 (1) DOI: 10.1038/s41467-020-18672-6). Their study focused on testing different scenarios that help explain how and why the lungs stop providing oxygen to the bloodstream.Read more in the article
A new diagnosis route based on blood test in the treatment of Alzheimer’s disease
Lately, an important aspect that researchers have paid attention to is addressing the discriminative accuracy of plasma phospho-tau217 (P-tau217) for differentiating Alzheimer disease from other neurodegenerative disorders. To this end, development of an inexpensive and widely available blood test for the presence of plaques and tangles is considered a potential breakthrough that would have a profound impact on Alzheimer's research and care.Read more in the article
Experimental drug agent pentagamavumon-1 (PGV-1) for stopping cancer growth
Scientists in Japan and Indonesia reported in a new study how an experimental drug agent stops cancer cells from growing. Their research was published in Scientific Reports (Pentagamavunon-1 (PGV-1) inhibits ROS metabolic enzymes and suppresses tumor cell growth by inducing M phase (prometaphase) arrest and cell senescence.Read more in the article
CytoSorbents awarded $4.4 Million Grant by the DoD for Universal Plasma Product
CytoSorbents Corporation was recently awarded a $4,421,487 three-year contract by the U.S. Department of Defense (DoD) to complete preclinical development of its HemoDefend-BGA plasma and whole blood adsorber. The advantage of this filter is that it is designed to allow a “universal plasma” that can be given to anyone no matter their blood type. The process essentially involves removing the anti-A and anti-B antibodies from the blood. This basically makes the blood “O” type that can be given to anyone [Source: https://www.biospace.com/]. Metabolic and inflammatory biomarkers associated with incident heart failure
Researchers showed that by measuring biomarkers indicative of heart failure, it could be possible to better identify people with an elevated risk of developing incident heart failure. In their study, they discovered several new biomarkers that were associated with incident heart failure. In this study, several inflammatory biomarkers and cell energy metabolites were linked to an increased risk of incident heart failure. The study employed a random selection of 10,106 men participating in the Metabolic Syndrome in Men (METSIM) study. These men at baseline did not have a diagnosis of incident heart failure. Researchers then measured elevated levels of inflammatory biomarkers and several biomarkers associated with heart metabolism by NMR analysis that were associated with the development of incident heart failure in a follow-up that lasted for 8.8 years. Read more in the article
Potential therapeutic target for clogged arteries
In a new research, researchers in the US reported a protein critical for the synthesis of ApoB-containing lipoproteins. This protein, called MTP, or microsomal triglyceride transfer protein, is shown to be highly conserved in animals, from insects to humans. Researchers have shown that MTP loads lipids onto ApoB, a key initial step in the synthesis of ApoB-containing lipoproteins. Read more in the article
Educational videos
https://www.youtube.com/c/BiotechnologyKiosk